Switching from protease inhibitors to a single-class regimen of abacavir/lamivudine/zidovudine plus tenofovir in patients with HIV load suppression [1]

AIDS

Volumn 19, Issue 8, 2005, Pages 841-842

  D'Ettorre, Gabriella ^a   Mastroianni, Claudio M ^a   Massetti, Anna P ^a   Lichtner, Miriam ^a   D'Agostino, Claudia ^a   Vullo, Vincenzo ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTILIPEMIC AGENT; ANTIRETROVIRUS AGENT; CHOLESTEROL; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; LIPID; LOPINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; TRIACYLGLYCEROL; ZIDOVUDINE;

ADULT; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG SAFETY; DRUG SUBSTITUTION; DYSLIPIDEMIA; DYSPEPSIA; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; LIPID BLOOD LEVEL; MALE; NAUSEA; PRIORITY JOURNAL; TREATMENT WITHDRAWAL; TRIACYLGLYCEROL BLOOD LEVEL; VIRUS LOAD;

EID: 20644434386     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.aids.0000168983.28079.87     Document Type: Letter

References (8)

1. Drechsler H, Powderly WG. Switching effective antiretroviral therapy: a review. Clin Infect Dis 2002; 35:1219-1230.
2. Bucher HC, Young J, Battegay M. Protease inhibitor-sparing simplified maintenance therapy: a need for perspective. J Antimicrob Chemother 2004; 54:303-305.
3. Martinez E, Arnaiz JA, Podzamczer D, Dalmau D, Ribera E, Domingo P, et al. Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection. N Engl J Med 2003; 349:1036-1046.
4. Gil P, de Gorgolas M, Estrada V. Long-term efficacy and safety of protease inhibitor switching to nevirapine in HIV-infected patients with undetectable virus load. Clin Infect Dis 2004; 39:1024-1029.
5. Opravil M, Hirschel B, Lazzarin A, Furrer H, Chave JP, Yerly S, et al. A randomized trial of simplified maintenance therapy with abacavir, lamivudine, and zidovudine in human immunodeficiency virus infection. J Infect Dis 2002; 185:1251-1260.
6. Opravil M, Baumann D, Chave JP, Furrer H, Calmy A, Bernasconi E, et al. Long-term efficacy after switch from protease inhibitor-containing highly active antiretroviral therapy to abacavir, lamivudine, and zidovudine. AIDS 2004; 18:2213-2215.
7. Maggiolo F, Ripamonti D, Ravasio L, Cregis G, Quinzan G, Callegaro A, et al. Outcome of 2 simplification strategies for the treatment of human immunodeficieny virus type 1 infection. Clin Infect Dis 2003; 37:41-49.
8. Domingo P, Labarga P, Palacios R, Guerrero MF, Terron JA, Elias MJP, et al. Improvement of dyslipidemia in patients switching from stavudine to tenofovir: preliminary results. AIDS 2004; 18:1475-1478.